Table 2.
Detailed of COVID-19 vaccine candidates designed for alternative delivery
| S. no | Vaccine candidate name | Company | Feature | Delivery route | Clinical phase |
|---|---|---|---|---|---|
| 1. | CoviVac | Codagenix USA and Serum Institute, India | Live attenuated | Intranasal | 1 |
| 2. | CIGB-669 (Mambisa) | Centre for Genetic Engineering and Biotechnology, Cuba | Protein subunit | Intranasal | 2 |
| 3. | BBV154 | Washington University School of Medicine in St. Louis, USA and Bharat Biotech, India | ChAd viralvector expressing spike protein | Intranasal | 1 |
| 4. | AdCOVID | Altimmune Inc. USA and University of Alabama Birmingham, USA | Non-replicating Adenovirus type 5 expressing the RBD of SARS-CoV-2 spike protein | Single dose Intranasal | Pre-clinical investigation |
| 5. | Unnamed | BlueWillow Biologics, USA and Medigen Vaccine Biologics Corporation, Taiwan | Oil-in-water nanoemulsion as carrier and adjuvant | Intranasal | Pre-clinical investigation |
| 6. | VXA-CoV2-1 | Vaxart Inc., USA | Non-replicating Adenovirus type 5 containing S and N proteins | Oral tablet | 1 |
| 7. | OraPro-COVID-19 | iosBio Pharma (earlier known as Stabilitech Biopharma), UK | Non-replicating Adenovirus type 5 containing spike protein DNA of SARS-CoV-2 | Oral capsule | 1 |